| |
|
|
|
Strategic Research Institute, Marriott La Jolla
February 28-March 1, 2005
This year’s program will spotlight an interactive panel discussion where leaders in field will discuss varies topics such as: meaningful selectivity, drugability of kinases, relevance of animal models to clinical experience, pitfalls for failures in kinase clinical programs and more. Panel participants include: Doriano Fabbro (Novartis Pharma AG), Tony Hunter (The Salk Institute), Blaine Knight (GlaxoSmithKline), Steven Pelech (Kinexus Bioinformatics) and discussion leader, Peter Blume-Jensen (Serono Reproductive Biology Institute).
In two days, you’ll be quickly updated on the state-of-the-art of protein kinase and phosphatase-based therapeutics, and come away with an overall perspective that shall enable you to apply what you learn to your own in-house efforts, select new avenues for investigation, or prospect new partners for licensing and other collaborations.We look forward to welcoming you in San Diego!
|
|
|
|
|
|
|
|
Organized by:
|
|
Strategic Research Institute |
|
|
Invited Speakers:
|
|
Protein Kinases and Disease in the Postgenomic Era”
Tony Hunter, Ph.D.
Professor, Molecular and Cell Biology Laboratory
The Salk Institute “Protein Kinase Inhibitors – Lessons Learned”
Doriano Fabbro, Ph.D.
Head in Signalling Pathways
Novartis Pharma AG
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
.
|
|
|
|
|
|
|
|
Registration:
|
|
3rd Annual
Protein Phosphorylation Drug Discovery World SummitFebruary 28 - March 1, 2005
Select Pricing Option
$1,395.00 1. Standard rate for Delegates
$795.00 2. Full-time Government Employee or Academic Rate
|
|
|
E-mail:
|
|
sgrodsky@srinstitute.com
|
|
|
|
|
|
|
|
|